Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology

Patent issuance expands U.S. patent portfolio for AVERSA™ transdermal abuse deterrent technology   Orlando, FL – September 20, 2023 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that the United States Patent and Trademark Office (USPTO) has granted US Patent No. 11,759,431 for Nutriband’s proprietary AVERSA™ abuse deterrent technology utilizing […]

Nutriband Inc. Receives Notice of Allowance from Korean Intellectual Property Office (KIPO) for its ‘Abuse and Misuse Deterrent Transdermal System’ Patent

Orlando, FL –  December 10, 2020 – Nutriband Inc. (OTCQB: NTRB), a Nevada corporation (the “Company”) has received a notice of allowance from the Korean Intellectual Property Office (KIPO) for the ‘Abuse and Misuse Deterrent Transdermal Systems’ patent application filed by its clinical subsidiary 4P Therapeutics.   The patent underpins 4p Therapeutics’ abuse deterrent fentanyl […]

Nutriband Inc. (OTCQB: NTRB) to Host Investor Webinar to Discuss Acquisition of 4P Therapeutics Inc. & Other Important Recent Developments

ORLANDO, Fla., Aug. 23, 2018 /PRNewswire/ — Nutriband Inc. (OTCQB: NTRB), a pharmaceutical company developing and commercializing a portfolio of prescription pharmaceuticals, OTC’s and consumer products based around the science of transdermal/topical technologies, announced today that Gareth Sheridan, CEO, will host an audio and video webinar, slide presentation and live Q & A session for […]